629 related articles for article (PubMed ID: 32222897)
21. Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up.
Cao SM; Liu Z; Jia WH; Huang QH; Liu Q; Guo X; Huang TB; Ye W; Hong MH
PLoS One; 2011 Apr; 6(4):e19100. PubMed ID: 21544243
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
23. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
[No Abstract] [Full Text] [Related]
24. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
25. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma.
Jiang SQ; Liu Q
Ai Zheng; 2009 Feb; 28(2):177-80. PubMed ID: 19550133
[TBL] [Abstract][Full Text] [Related]
26. IgA directed against early antigen of Epstein-Barr virus is no specific marker for the diagnosis of nasopharyngeal carcinoma.
Sigel G; Schillinger M; Henninger K; Bauer G
J Med Virol; 1994 Jul; 43(3):222-7. PubMed ID: 7931181
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma].
Cai YL; Li J; Lu AY; Zhong WM; Zheng YM; Gao JQ; Zeng H; Chen WS; Liang W; Tang MZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):119-22. PubMed ID: 24044217
[TBL] [Abstract][Full Text] [Related]
28. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
[TBL] [Abstract][Full Text] [Related]
29. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
[TBL] [Abstract][Full Text] [Related]
30. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
31. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
[TBL] [Abstract][Full Text] [Related]
32. Plasma Macrophage Inhibitory Cytokine-1 as a Complement of Epstein-Barr Virus Related Markers in Identifying Nasopharyngeal Carcinoma.
Xing S; Li H; Pi Y; Zeng T; Huang Q; Ou G; Xue N
Technol Cancer Res Treat; 2020; 19():1533033820956991. PubMed ID: 33025864
[TBL] [Abstract][Full Text] [Related]
33. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
Clin Vaccine Immunol; 2009 May; 16(5):706-11. PubMed ID: 19321695
[TBL] [Abstract][Full Text] [Related]
34. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
[TBL] [Abstract][Full Text] [Related]
35. Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma.
Liu L; Zuo L; Yang J; Xin S; Zhang J; Zhou J; Li G; Tang J; Lu J
Cancer Med; 2019 Jun; 8(6):3142-3151. PubMed ID: 31063269
[TBL] [Abstract][Full Text] [Related]
36. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.
Tay JK; Siow CH; Goh HL; Lim CM; Hsu PP; Chan SH; Loh KS
Int J Cancer; 2020 May; 146(10):2923-2931. PubMed ID: 31705522
[TBL] [Abstract][Full Text] [Related]
37. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Value of Serum Epstein-Barr Virus Capsid Antigen-IgA for Nasopharyngeal Carcinoma: a Meta-Analysis Based on 21 Studies.
Chen Y; Xin X; Cui Z; Zheng Y; Guo J; Chen Y; Lin Y; Su G
Clin Lab; 2016; 62(6):1155-66. PubMed ID: 27468579
[TBL] [Abstract][Full Text] [Related]
39. Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma.
Xu XF; Lu RQ; Xiao R; Zhou L; Zhao XM; Hu XC; Gao X; Guo L
Cancer Biomark; 2016; 16(3):467-76. PubMed ID: 27062704
[TBL] [Abstract][Full Text] [Related]
40. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China.
Ji MF; Sheng W; Cheng WM; Ng MH; Wu BH; Yu X; Wei KR; Li FG; Lian SF; Wang PP; Quan W; Deng L; Li XH; Liu XD; Xie YL; Huang SJ; Ge SX; Huang SL; Liang XJ; He SM; Huang HW; Xia SL; Ng PS; Chen HL; Xie SH; Liu Q; Hong MH; Ma J; Yuan Y; Xia NS; Zhang J; Cao SM
Ann Oncol; 2019 Oct; 30(10):1630-1637. PubMed ID: 31373615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
